Iovance Biotherapeutics Q3 2023 EPS $(0.46) Misses $(0.45) Estimate, Sales $469.00K Miss $4.19M Estimate
Portfolio Pulse from totan@benzinga.com
Iovance Biotherapeutics reported Q3 2023 losses of $(0.46) per share, missing the analyst consensus estimate of $(0.45) by 2.22%. The company's quarterly sales were $469.00K, missing the estimate of $4.19M by 88.81%.
November 07, 2023 | 9:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Iovance Biotherapeutics reported lower than expected earnings and sales for Q3 2023.
Iovance Biotherapeutics reported a larger than expected loss per share and significantly lower sales than estimated for Q3 2023. This could negatively impact the company's stock price in the short term as it indicates weaker than expected financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100